fashion -WSS

fashion

author：focus 2025-10-01 18:07:29 - browse：54

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

WSS

UnitedHealth argues against case alleging wrongful AI care denials

Why the drug industry's warnings on the IRA's impact fall short

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Free Covid tests will again be offered to all U.S. households

Listen: A conversation with researcher Kevin Esvelt on biosecurity

PBMs drew scrutiny in House hearing — and so did pharma

Wikipedia

fashion

focus

At least 13 dead in Texas as scorching temps continue

Listen: More tumult at BIO & coercive care for sickle cell patients

Supreme Court strikes down use of affirmative action

UnitedHealth argues against case alleging wrongful AI care denials

BioMarin wins approval for gene therapy to treat hemophilia A

Listen: More tumult at BIO & coercive care for sickle cell patients

At least 13 dead in Texas as scorching temps continue

David Liu startup to focus on CRISPR delivery

DIEP, the 'gold standard' of breast reconstruction, is under threat

Senate bill would ban some hospital facility fees

knowledge

Assistant physicians can help address the primary care shortage

PBMs drew scrutiny in House hearing — and so did pharma

UnitedHealth argues against case alleging wrongful AI care denials

Liver decline slowed by off

How the messy conversation about Dolly changed bioethics

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

focus

explore

knowledge

explore